BMC Cancer

Table 1 Expression of ezrin, ezrin ^Thr-567 and ezrin ^Tyr-353 in NSCLC

From: Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer

		Ezrin		Ezrin^Thr-567		Ezrin^Tyr-353
Diagnosis	No. of cases	Positive rate	Strongly positive rate	Positive rate	Strongly positive rate	Positive rate	Strongly positive rate
		(+ ~ +++, %)	(++ ~ +++, %)	(+ ~ +++, %)	(++ ~ +++, %)	(+ ~ +++, %)	(++ ~ +++, %)
NSCLC	150	94 (62.7%)**	61 (40.7%)**	95 (63.3%)**	68 (45.3%)**	107 (71.3%)**	72 (48.0%)**
Adjacent non-tumor	150	47 (31.3%)	5 (3.3%)	21 (14.0%)	7 (4.7%)	17 (11.3%)	2 (1.3%)
Normal lung tissues	14	5 (35.7%)	0 (0.0%)	2 (14.3%)	0 (0.0%)	1 (7.1%)	0 (0.0%)

Positive rate: percentage of positive cases with ‘+’, ‘++’, and ‘+++’, Strongly positive rate: percentage of positive cases with ‘++’, and ‘+++’, **P < 0.01: NSCLC vs Adjacent non-tumor and Normal lung tissues.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com